Literature DB >> 12404057

Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories.

Peter Regitnig1, Angelika Reiner, Hans-Peter Dinges, Gerald Höfler, Elisabeth Müller-Holzner, Sigurd F Lax, Peter Obrist, Margaretha Rudas, Franz Quehenberger.   

Abstract

Steroid hormone receptors are important prognostic and predictive factors in breast carcinomas. Thus their determination is of essential importance. The aims of this study were to assess the quality of the immunohistochemical assays, and to assess the interlaboratory and interobserver variability performed by different laboratories in Austria. Ten unstained slides for interlaboratory variability evaluation and ten immunohistochemically prestained slides for interobserver variability evaluation from breast carcinomas known to show different degrees of steroid hormone receptor expressions were sent to 32 surgical pathology laboratories in Austria (participation rate 97%). The participants were requested to perform their in-house immunohistochemistry (IHC) technique for estrogen receptors (ERs) and progesterone receptors (PRs) on the unstained slides. All slides were evaluated by estimating percentage and intensity of stained nuclei semiquantitatively. From these data the Reiner, Remmele and the Allred scores were calculated. A less than 10% cut-off level was chosen as threshold for positive cases. Regarding the series of prestained slides, both sensitivity and specificity were very high (>96.88%); false-positive and -negative rates were low (<3.31%). Interobserver variability showed moderate multirater kappa values concerning the ER (Reiner score: kappa=0.57) and PR scores (Reiner score: kappa=0.53). The agreement among observers was better for negative cases than positive cases. In-house slides representing interlaboratory variability showed fair to moderate kappa values concerning the ER and PR scores (kappa for ER Reiner score=0.41; PR=0.32). In this slide series, sensitivity and specificity were high (>82.2%) and false-positive or -negative rates were low in ER cases (<3.03) and moderately low in PR cases (17.46%). These results demonstrate that variability is higher when participants use their own staining method. In more detailed analysis, the automated IHC techniques showed an advantage over manual techniques concerning interlaboratory variability. There exists no difference in reproducibility with respect to scoring systems for steroid hormone receptor estimation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12404057     DOI: 10.1007/s00428-002-0646-5

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

Review 1.  Practical implications of gene-expression-based assays for breast oncologists.

Authors:  Aleix Prat; Matthew J Ellis; Charles M Perou
Journal:  Nat Rev Clin Oncol       Date:  2011-12-06       Impact factor: 66.675

2.  External Quality Assurance in Immunohistochemistry - Is It the Solution to a Complex Problem?

Authors:  Angelika Reiner-Concin
Journal:  Breast Care (Basel)       Date:  2008-04-22       Impact factor: 2.860

Review 3.  The changing role of pathology in breast cancer diagnosis and treatment.

Authors:  Anthony S-Y Leong; Zhengping Zhuang
Journal:  Pathobiology       Date:  2011-06-14       Impact factor: 4.342

4.  Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform.

Authors:  Minseok S Kim; Taemin Kim; Sun-Young Kong; Soim Kwon; Chae Yun Bae; Jaekyu Choi; Chul Hwan Kim; Eun Sook Lee; Je-Kyun Park
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

5.  Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study.

Authors:  C A Wells; J P Sloane; D Coleman; C Munt; I Amendoeira; N Apostolikas; J P Bellocq; S Bianchi; W Boecker; G Bussolati; C E Connolly; P Dervan; M Drijkoningen; I O Ellis; C W Elston; V Eusebi; D Faverly; P Heikkila; R Holland; J Jacquemier; M Lacerda; J Martinez-Penuela; C De Miguel; J L Peterse; F Rank; A Reiner; E Saksela; B Sigal-Zafrani; M Sylvan; B Borisch; G Cserni; T Decker; H Kerner; J Kulka; P Regitnig; A Sapino; A M Tanous; S Thorstenson; E Zozaya
Journal:  Virchows Arch       Date:  2004-06-24       Impact factor: 4.064

6.  Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis.

Authors:  Jens Neumann; Laura Wehweck; Susanne Maatz; Jutta Engel; Thomas Kirchner; Andreas Jung
Journal:  Virchows Arch       Date:  2013-08-10       Impact factor: 4.064

7.  DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Joshua Whorton; Sripathi M Sureban; Randal May; Dongfeng Qu; Stan A Lightfoot; Mohammad Madhoun; Milton Johnson; William M Tierney; John T Maple; Kenneth J Vega; Courtney W Houchen
Journal:  Dig Dis Sci       Date:  2014-10-05       Impact factor: 3.199

8.  Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer.

Authors:  António E Pinto; Filipa Areia; Teresa Pereira; Paula Cardoso; Mariana Aparício; Giovani L Silva; Mónica C Ferreira; Saudade André
Journal:  Springerplus       Date:  2013-08-09

9.  Putting the brakes on mammary tumorigenesis: loss of STAT1 predisposes to intraepithelial neoplasias.

Authors:  Christine Schneckenleithner; Zsuzsanna Bago-Horvath; Helmut Dolznig; Nina Neugebauer; Karoline Kollmann; Thomas Kolbe; Thomas Decker; Dontscho Kerjaschki; Kay-Uwe Wagner; Mathias Müller; Dagmar Stoiber; Veronika Sexl
Journal:  Oncotarget       Date:  2011-12

10.  Update on triple-negative breast cancer: prognosis and management strategies.

Authors:  Olivier Brouckaert; Hans Wildiers; Giuseppe Floris; Patrick Neven
Journal:  Int J Womens Health       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.